CL2017001364A1 - Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos. - Google Patents

Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.

Info

Publication number
CL2017001364A1
CL2017001364A1 CL2017001364A CL2017001364A CL2017001364A1 CL 2017001364 A1 CL2017001364 A1 CL 2017001364A1 CL 2017001364 A CL2017001364 A CL 2017001364A CL 2017001364 A CL2017001364 A CL 2017001364A CL 2017001364 A1 CL2017001364 A1 CL 2017001364A1
Authority
CL
Chile
Prior art keywords
preparation
well
procedures
diseases
endometriosis
Prior art date
Application number
CL2017001364A
Other languages
English (en)
Inventor
Holger Siebeneicher
Christian Stegmann
Ulf Boemer
Ulrich Bothe
Nicole Schmidt
Reinhard Nubbemeyer
Judith Günther
Holger Steuber
Martin Lange
Andreas Sutter
Alexandra Rausch
Christian Friedrich
Peter Hauff
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2017001364A1 publication Critical patent/CL2017001364A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>LA PRESENTE SOLICITUD SE REFIERE A NUEVOS INDAZOLES SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACIÓN, SU USO SOLOS O EN COMBINACIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES, ASÍ COMO SU USO PARA LA PREPARACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES, EN ESPECIAL PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DE ENDOMETRIOSIS, ASÍ COMO DOLORES ASOCIADOS CON ENDOMETRIOSIS Y OTROS SÍNTOMAS ASOCIADOS CON ENDOMETRIOSIS COMO DISMENORREA, DISPAREUNIA, DISURIA Y DISQUECIA, DE LINFOMAS, ARIRITIS REUMATOIDEA, ESPONDILOARTRITIS (EN ESPECIAL ESPONDILOARTRITIS PSORIÁSICA Y ENFERMEDAD DE BECHTEREW), LUPUS ERITEMATOSO, ESCLEROSIS MÚLTIPLE, DEGENERACIÓN MACULAR, EPOC, GOTA,  ENFERMEDADES DE HÍGADO GRASO, INSUFICIENCIA INSULÍNICA, ENFERMEDADES TUMORALES Y PSORIASIS.</p>
CL2017001364A 2014-11-26 2017-05-26 Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos. CL2017001364A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14195032 2014-11-26

Publications (1)

Publication Number Publication Date
CL2017001364A1 true CL2017001364A1 (es) 2017-12-15

Family

ID=51982455

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001364A CL2017001364A1 (es) 2014-11-26 2017-05-26 Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.

Country Status (42)

Country Link
US (6) US10308634B2 (es)
EP (3) EP3674298B9 (es)
JP (1) JP6496823B2 (es)
KR (1) KR102083857B1 (es)
CN (2) CN107406416B (es)
AR (1) AR102827A1 (es)
AU (2) AU2015352603B2 (es)
BR (2) BR112017011005B1 (es)
CA (1) CA2968614C (es)
CL (1) CL2017001364A1 (es)
CO (1) CO2017005374A2 (es)
CR (1) CR20170220A (es)
CU (1) CU24448B1 (es)
CY (1) CY1123815T1 (es)
DK (2) DK3224254T3 (es)
DO (1) DOP2017000127A (es)
EA (1) EA032509B1 (es)
EC (1) ECSP17032530A (es)
ES (2) ES2976932T3 (es)
FI (1) FI3674298T3 (es)
HR (2) HRP20200974T1 (es)
HU (2) HUE049341T2 (es)
IL (3) IL252185B (es)
JO (1) JO3705B1 (es)
LT (2) LT3224254T (es)
MA (1) MA41011B1 (es)
ME (1) ME03745B (es)
MX (2) MX390119B (es)
NI (1) NI201700063A (es)
NZ (1) NZ732126A (es)
PE (1) PE20171376A1 (es)
PH (1) PH12017500972A1 (es)
PL (2) PL3674298T3 (es)
PT (2) PT3224254T (es)
RS (2) RS65327B1 (es)
SG (3) SG10201903474PA (es)
SI (2) SI3674298T1 (es)
TN (1) TN2017000226A1 (es)
TW (2) TWI689502B (es)
UA (2) UA123813C2 (es)
UY (1) UY36411A (es)
WO (1) WO2016083433A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605408RA (en) 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
FI3805233T3 (fi) 2014-01-13 2024-04-17 Aurigene Oncology Ltd N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es) * 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
EP3195865A1 (de) * 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
EP3423446B1 (de) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
KR102409105B1 (ko) * 2016-04-29 2022-06-16 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
UA123169C2 (uk) * 2016-04-29 2021-02-24 Байєр Фарма Акцієнгезелльшафт Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду
EA035867B1 (ru) * 2016-04-29 2020-08-24 Байер Фарма Акциенгезельшафт Синтез индазолов
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
MY199070A (en) 2016-06-01 2023-10-12 Bayer Pharma AG Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
UA125650C2 (uk) 2016-09-09 2022-05-11 Інсайт Корпорейшн Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018060072A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒&#134116;衍生物
DK3600270T3 (da) 2017-03-31 2023-07-10 Aurigene Oncology Ltd Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
IL272575B2 (en) 2017-08-16 2023-09-01 Univ Vanderbilt Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
PE20210368A1 (es) 2018-06-27 2021-02-26 Eth Zuerich Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
CN112119068A (zh) 2018-06-27 2020-12-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物
JP7456948B2 (ja) 2018-06-27 2024-03-27 エフ． ホフマン－ラ ロシュ アーゲー 放射性標識カンナビノイド受容体２リガンド
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
WO2020035019A1 (zh) * 2018-08-17 2020-02-20 浙江海正药业股份有限公司 吲唑胺类衍生物及其制备方法和其在医药上的用途
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
EP3889150A4 (en) * 2018-12-25 2022-02-23 Shanghai Meiyue Biotech Development Co., Ltd. COMPOUND SERVING AS IRAQ INHIBITOR
CN111362920B (zh) * 2018-12-25 2024-06-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN111560012B (zh) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111793064B (zh) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
WO2020259626A1 (zh) * 2019-06-26 2020-12-30 南京明德新药研发有限公司 作为irak4抑制剂的咪唑并吡啶类化合物
JP2022539374A (ja) * 2019-06-27 2022-09-08 バイオジェン・エムエイ・インコーポレイテッド ２ｈ－インダゾール誘導体及び疾患の処置におけるそれらの使用
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
WO2021007477A1 (en) 2019-07-11 2021-01-14 E-Scape Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
MX2022001562A (es) 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
US20220298139A1 (en) * 2019-09-24 2022-09-22 Shanghai Meiyue Biotech Development Co., Ltd. Irak inhibitor and preparation method therefor and use thereof
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
KR20240004476A (ko) 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
CN113278017B (zh) * 2021-05-27 2023-03-28 上海应用技术大学 取代吲唑类化合物、制备方法、应用和包含其的组合物
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
WO2023283372A1 (en) * 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途
CN119894895A (zh) 2022-11-04 2025-04-25 领泰生物医药(绍兴)有限公司 Irak4降解剂及其用途
EP4618984A1 (en) * 2022-11-17 2025-09-24 Elanco Animal Health GmbH Methods and compositions for control of pain and inflammation
CN116120283B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种氘代啶酰胺类irak-4抑制剂药物及用途
KR20250004525A (ko) * 2023-06-29 2025-01-08 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
CA2493026C (en) * 2002-07-31 2011-05-24 Bayer Schering Pharma Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines
ATE500216T1 (de) 2003-06-25 2011-03-15 Je Il Pharmaceutical Co Ltd Tricyclische derivate oder pharmazeutisch unnbedenkliche salze davon, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
WO2006061715A2 (en) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Methylene inhibitors of matrix metalloproteinase
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
TWI435863B (zh) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd Ｎ-２-（雜）芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
KR20090049076A (ko) * 2006-09-07 2009-05-15 바이오겐 아이덱 엠에이 인코포레이티드 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
BR112013020270A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
JP5940562B2 (ja) 2011-02-18 2016-06-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2852596B1 (en) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Thienopyrimidines
JP2015002717A (ja) 2013-06-21 2015-01-08 住友ベークライト株式会社 蓋付き容器
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en) * 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
JP2017518348A (ja) 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es) 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
EP3423446B1 (de) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
KR102409105B1 (ko) 2016-04-29 2022-06-16 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
UA123169C2 (uk) 2016-04-29 2021-02-24 Байєр Фарма Акцієнгезелльшафт Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду
MY199070A (en) 2016-06-01 2023-10-12 Bayer Pharma AG Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Also Published As

Publication number Publication date
US12006303B2 (en) 2024-06-11
AU2015352603B2 (en) 2020-04-02
IL269444B (en) 2020-07-30
BR112017011005A2 (pt) 2019-05-14
SG10201903475TA (en) 2019-05-30
EP3224254B1 (de) 2020-04-15
ES2976932T3 (es) 2024-08-13
PE20171376A1 (es) 2017-09-15
PH12017500972A1 (en) 2017-12-18
US20230174508A1 (en) 2023-06-08
PL3224254T3 (pl) 2020-09-21
EP3224254A1 (de) 2017-10-04
SG11201704092YA (en) 2017-06-29
AU2020200979A1 (en) 2020-02-27
SI3224254T1 (sl) 2020-07-31
MA41011B1 (fr) 2020-08-31
LT3674298T (lt) 2024-04-10
ES2976932T9 (es) 2024-09-05
CA2968614C (en) 2019-10-29
PT3224254T (pt) 2020-06-17
SG10201903474PA (en) 2019-05-30
TWI689502B (zh) 2020-04-01
JP6496823B2 (ja) 2019-04-10
US20170349570A1 (en) 2017-12-07
EP4260909A3 (de) 2024-03-20
IL269444A (en) 2019-11-28
IL252185B (en) 2019-10-31
RS60284B1 (sr) 2020-06-30
MX390119B (es) 2025-03-20
UA123813C2 (uk) 2021-06-02
BR112017011005B1 (pt) 2023-03-14
CN107406416B (zh) 2020-04-21
US12006304B2 (en) 2024-06-11
CU24448B1 (es) 2019-10-04
HRP20200974T1 (hr) 2020-10-02
US12559473B2 (en) 2026-02-24
CA2968614A1 (en) 2016-06-02
NZ732126A (en) 2018-09-28
UY36411A (es) 2016-06-30
IL267537B (en) 2020-07-30
EP3674298B1 (de) 2024-01-10
CO2017005374A2 (es) 2017-08-31
KR20170085590A (ko) 2017-07-24
NI201700063A (es) 2017-07-17
US20210053941A1 (en) 2021-02-25
JP2017535585A (ja) 2017-11-30
JO3705B1 (ar) 2021-01-31
CN110305109B (zh) 2022-04-08
CN110305109A (zh) 2019-10-08
SI3674298T1 (sl) 2024-05-31
BR122021002613B1 (pt) 2023-04-11
MX2017006910A (es) 2017-08-15
EA032509B1 (ru) 2019-06-28
EP3674298A1 (de) 2020-07-01
HUE065938T2 (hu) 2024-06-28
ECSP17032530A (es) 2017-06-30
EP3674298B9 (de) 2024-06-19
EP4260909A2 (de) 2023-10-18
LT3224254T (lt) 2020-06-10
US20250034111A1 (en) 2025-01-30
UA120948C2 (uk) 2020-03-10
TW201629037A (zh) 2016-08-16
FI3674298T3 (fi) 2024-04-17
US20190233395A1 (en) 2019-08-01
US20220388982A1 (en) 2022-12-08
AU2015352603A1 (en) 2017-06-01
RS65327B1 (sr) 2024-04-30
CR20170220A (es) 2017-10-31
ES2796285T3 (es) 2020-11-26
WO2016083433A1 (de) 2016-06-02
IL267537A (en) 2019-08-29
EA201791137A1 (ru) 2017-11-30
TWI717061B (zh) 2021-01-21
CY1123815T1 (el) 2022-03-24
DK3224254T3 (da) 2020-07-13
TN2017000226A1 (en) 2018-10-19
MX2020010623A (es) 2022-02-16
ME03745B (me) 2021-04-20
AU2020200979B2 (en) 2021-01-07
IL252185A0 (en) 2017-07-31
PT3674298T (pt) 2024-04-01
PL3674298T3 (pl) 2024-06-24
CU20170073A7 (es) 2017-10-05
KR102083857B1 (ko) 2020-03-03
MX380150B (es) 2025-03-12
US10308634B2 (en) 2019-06-04
HRP20240414T1 (hr) 2024-06-21
CN107406416A (zh) 2017-11-28
AR102827A1 (es) 2017-03-29
DK3674298T3 (da) 2024-04-08
HUE049341T2 (hu) 2020-09-28
DOP2017000127A (es) 2017-07-31
US10793545B2 (en) 2020-10-06
TW202002973A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
UY37048A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2016001579A1 (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos.
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
DOP2015000100A (es) Inhibidores de la tirosina-quinasa de bruton
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CR20150007A (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CR20180200A (es) Ciano tienotriazolpirazinas y usos de las mismas
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.